Cambridge Nutritional Sciences (FRA:RVKA) 3-Year Share Buyback Ratio: -9.20% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cambridge Nutritional Sciences 3-Year Share Buyback Ratio?

Cambridge Nutritional Sciences FRA:RVKA 3-Year Share Buyback Ratio is -9.20 as of Sep. 2025. The stock has 3 warning signs investors should review. Among 615 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks worse than 69.27% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cambridge Nutritional Sciences's current 3-Year Share Buyback Ratio was -9.20%.

The historical rank and industry rank for Cambridge Nutritional Sciences's 3-Year Share Buyback Ratio or its related term are showing as below:

FRA:RVKA' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -319.5   Med: -11.4   Max: 0
Current: -9.2

During the past 13 years, Cambridge Nutritional Sciences's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -319.50%. And the median was -11.40%.

FRA:RVKA's 3-Year Share Buyback Ratio is ranked worse than
69.27% of 615 companies
in the Medical Devices & Instruments industry
Industry Median: -2.6 vs FRA:RVKA: -9.20

Cambridge Nutritional Sciences (FRA:RVKA) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Cambridge Nutritional Sciences 3-Year Share Buyback Ratio Related Terms


FRA:RVKA vs ISRG, BDX, RMD: 3-Year Share Buyback Ratio Comparison

For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambridge Nutritional Sciences 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Cambridge Nutritional Sciences's 3-Year Share Buyback Ratio falls into.



Cambridge Nutritional Sciences 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -9.20 mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a 3-Year Share Buyback Ratio of -9.20 as of Sep. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cambridge Nutritional Sciences and its competitors. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #426 out of 615 companies in the Medical Devices & Instruments industry, placing it in the top 69.3%.
Is Cambridge Nutritional Sciences' 3-Year Share Buyback Ratio too high?
Cambridge Nutritional Sciences' current 3-Year Share Buyback Ratio is -9.20. Based on the distribution chart, Cambridge Nutritional Sciences ranks #426 out of 615 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Cambridge Nutritional Sciences' 3-Year Share Buyback Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #426 out of 615 companies for 3-Year Share Buyback Ratio. This places Cambridge Nutritional Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cambridge Nutritional Sciences and its competitors. Cambridge Nutritional Sciences's current 3-Year Share Buyback Ratio is -9.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 27.5% below its estimated fair value. The current 3-Year Share Buyback Ratio is -9.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current 3-Year Share Buyback Ratio is -9.20 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambridge Nutritional Sciences Business Description

Other Exchanges CNSL:UK
Address One Fleet Place, London, GBR, EC4M 7WS
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.